Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-κB signaling pathway activation in vascular endothelial cells

被引:64
作者
Kawanami, Daiji [1 ]
Matoba, Keiichiro [1 ]
Kanazawa, Yasushi [1 ]
Ishizawa, Sho [1 ]
Yokota, Tamotsu [1 ]
Utsunomiya, Kazunori [1 ]
机构
[1] Jikei Univ Sch Med, Dept Internal Med, Div Diabet Metab & Endocrinol, Minato Ku, Tokyo 1058461, Japan
基金
日本学术振兴会;
关键词
Rho-kinase; Thrombin; Atherosclerosis; Endothelial cells; DIABETIC DB/DB MICE; LEUKOCYTE RECRUITMENT; ADHESION MOLECULE-1; GENE-EXPRESSION; P38; MAPK; ATHEROSCLEROSIS; NEPHROPATHY; INHIBITOR; RECEPTOR-1; DISEASE;
D O I
10.1016/j.bbrc.2011.07.031
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Thrombin has been shown to increase expression of chemokines such as monocyte chemoattractant protein 1 (MCP-1) in endothelial cells, leading to the development of atherosclerosis. However, the precise mechanism of this induction remains unknown. In the present study, we investigated whether the small G protein RhoA, and its effector. Rho-kinase are involved in MCP-1 induction by thrombin in endothelial cells. Y-27632, a specific Rho-kinase inhibitor, potently inhibited MCP-1 induction by thrombin. Y-27632 significantly decreased the chemotactic activity of thrombin-stimulated supernatants of endothelial cells on monocytes. Importantly, fasudil, a specific Rho-kinase inhibitor, attenuated MCP-1 gene expression in the aorta of db/db mice. Y-27632 attenuated thrombin-mediated phosphorylation of p38MAPK and p65, indicating that Rho-kinase mediates thrombin-induced MCP-1 expression through p38MAPK and NF-kappa B activation. Our findings demonstrate that the Rho/Rho-kinase signaling pathway plays a critical role in thrombin-mediated MCP-1 expression and function, and suggest that Rho/Rho-kinase may be an important target in the development of new therapeutic strategies for atherosclerosis. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:798 / 803
页数:6
相关论文
共 33 条
[1]
RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of IκB kinase β and phosphorylation of RelA/p65 [J].
Anwar, KN ;
Fazal, F ;
Malik, AB ;
Rahman, A .
JOURNAL OF IMMUNOLOGY, 2004, 173 (11) :6965-6972
[2]
Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy [J].
Asakawa, H ;
Tokunaga, K ;
Kawakami, F .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2000, 14 (03) :121-126
[3]
Rho kinase inhibition: A new approach for treating diabetic nephropathy? [J].
Bach, Leon A. .
DIABETES, 2008, 57 (03) :532-533
[4]
The specific role of chemokines in atherosclerosis [J].
Braunersreuther, Vincent ;
Mach, Francois ;
Steffens, Sabine .
THROMBOSIS AND HAEMOSTASIS, 2007, 97 (05) :714-721
[5]
HYPERGLYCEMIA-INDUCED THROMBIN FORMATION IN DIABETES - THE POSSIBLE ROLE OF OXIDATIVE STRESS [J].
CERIELLO, A ;
GIACOMELLO, R ;
STEL, G ;
MOTZ, E ;
TABOGA, C ;
TONUTTI, L ;
PIRISI, M ;
FALLETI, E ;
BARTOLI, E .
DIABETES, 1995, 44 (08) :924-928
[6]
Protein Kinase C-related Kinase and ROCK Are Required for Thrombin-induced Endothelial Cell Permeability Downstream from Gα12/13 and Gα11/q [J].
Gavard, Julie ;
Gutkind, J. Silvio .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (44) :29888-29896
[7]
The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats [J].
Gojo, Atsushi ;
Utsunomiya, Kazunori ;
Taniguchi, Kanta ;
Yokota, Tamotsu ;
Ishizawa, Shoh ;
Kanazawa, Yasushi ;
Kurata, Hideaki ;
Tajima, Naoko .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 568 (1-3) :242-247
[8]
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice [J].
Gu, L ;
Okada, Y ;
Clinton, SK ;
Gerard, C ;
Sukhova, GK ;
Libby, P ;
Rollins, BJ .
MOLECULAR CELL, 1998, 2 (02) :275-281
[9]
Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms [J].
Jain, MK ;
Ridker, PM .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (12) :977-987
[10]
Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors [J].
Juhan-Vague, I ;
Renucci, JF ;
Grimaux, M ;
Morange, PE ;
Gouvernet, J ;
Gourmelin, Y ;
Alessi, MC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (09) :2156-2161